Clinical Trial Update: AMPK-activation by Metformin in FSGS: AMP-FSGS [Phase 1, Phase 2]

View source ↗

Summary

A Yale-sponsored clinical trial is investigating metformin to activate AMPK as a potential treatment for focal segmental glomerulosclerosis, currently in Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Yale University | Conditions: Focal Segmental Glomerulosclerosis | Phase 1, Phase 2 | Status: RECRUITING